

## Tumor Experience

Cancer	Phase	# of	# of	Year	Year
		Patients	Sites	Started	Completed
AML	II	40	5	2001	2003
Breast--1 <sup>st</sup> line Met	IV	300	70	2001	2004
Breast--1 <sup>st</sup> line Met	II	51	21	2003	2007
Breast--1 <sup>st</sup> line Met	II	72	29	2005	2008
Breast--Adjuvant ER+	III	117	8	2006	2008
Breast--2 <sup>nd</sup> line Met	III	7	3	2006	2008
Breast--1 <sup>st</sup> line Met	III	17	7	2006	2007
Breast--1 <sup>st</sup> line Met	II	16	15	2007	2008
Breast--1 <sup>st</sup> line Met	II	32	14	2008	Ongoing
Breast--1 <sup>st/2nd</sup> line Met	II	5	5	2008	2009
Breast--Adjuvant	IV	49	9	2008	2009
Breast--1 <sup>st/2nd</sup> line Erb2+	II	10	9	2008	Ongoing
Breast--2 <sup>nd</sup> line ER+	III	0	7	2009	Pending
Breast--1 <sup>st</sup> line HER+	III	4	8	2009	Pending
Ovarian--2 <sup>nd</sup> Line	II	4	5	2008	2009
NSCLC	II b	110	20	2003	2005
Lung	Epidemiology	3000	65	2006	Ongoing
NSCLC--1 <sup>st</sup> line	II	82	21	2004	2008
NSCLC--2 <sup>nd</sup> line	II	7	9	2004	2006
NSCLC--1 <sup>st</sup> line	II	69	22	2005	2007
NSCLC--2 <sup>nd</sup> line	II	70	15	2005	2007
NSCLC--1 <sup>st</sup> line	III	15	4	2006	2008
NSCLC--Advanced	II	10	8	2007	2008
NSCLC--1 <sup>st</sup> line	II	83	18	2006	Ongoing
NSCLC--2 <sup>nd/3rd</sup> line	III	10	8	2007	Ongoing
NSCLC--2 <sup>nd</sup> line	III	7	9	2008	Ongoing
NSCLC--1 <sup>st</sup> line	III	0	3	2009	Pending
NSCLC--1 <sup>st</sup> line	III	0	11	2009	Ongoing
NSCLC--1 <sup>st</sup> line	III	32	15	2009	Ongoing
NSCLC--2 <sup>nd</sup> line	III	14	9	2009	Ongoing
NSCLC-1 <sup>st</sup> line with Radiation	III	0	III	2009	Ongoing
NSCLC – 1 <sup>st</sup> line	III	11	8	2008	Ongoing
SCLC--2 <sup>nd</sup> line	III	36	11	2008	Ongoing
SCLC--1 <sup>st</sup> line	I	34	14	2008	Ongoing
Rectum	II	87	16	2003	2008
Colorectal--1 <sup>st</sup> line	II	82	19	2004	2008
Colorectal--1 <sup>st</sup> line	III	57	31	2005	2007
Colorectal--2 <sup>nd</sup> line	II	39	15	2006	2007
Colorectal--1 <sup>st</sup> line	IIb	31	9	2008	Ongoing
Colorectal--2 <sup>nd</sup> line	II	2	3	2008	Ongoing
Colorectal--1 <sup>st</sup> line	II	6	6	2008	2009

Cancer	Phase	# of Patients	# of Sites	Year Started	Year Completed
Colorectal--1st line	II	0	4	2009	Ongoing
Pancreatic--1st line	II	8	20	2003	2004
Prostate	1a	65	5	2008	2009
Prostate	IV	79	12	2004	Ongoing
Prostate	IV	160	50	2003	2006
Prostate	Epidemiology	120	1	2007	2008
Prostate	II a	80	6	2007	Ongoing
Prostate	III a	250	50	2002	2004
HRPC--1 <sup>st</sup> line	II	35	22	2006	2008
HRPC--1 <sup>st</sup> line	III	11	10	2007	2007
HRPC--2 <sup>nd</sup> line and beyond	EAP	40	16	2007	2007
Kidney	I	10	5	2004	2007
Kidney	Epidemiology	35	1	2008	2008
Renal cell--1 <sup>st</sup> line	III	45	8	2006	2008
Renal cell--1 <sup>st</sup> line	III	6	6	2008	Ongoing
Renal cell--1 <sup>st</sup> line	III	6	3	2009	Ongoing
Hodgkin's Lymphoma	I	18	1	2006	Ongoing
Hodgkin's Lymphoma	I	12	1	2007	2009
NHL	III	320	42	2007	2008
CLL	IV	210	25	2007	2007
Mantle Cell Lymphoma --2 <sup>nd</sup> line	II	8	25	2008	Ongoing
MDS--1 <sup>st</sup> line	II	15	13	2004	2006
MDS--1 <sup>st</sup> line	III	0	5	2009	Ongoing
Biliary tract	II	61	6	2003	2007
Melano-carcinoma	II a	152	2	2007	2008
Melanoma--1 <sup>st</sup> line	II	11	5	2007	2008
Head and Neck	Investigator-initiated study	75	1	2007	Ongoing
Glioblastoma	IV	150	12	2000	2004
Multiple Myeloma--1 <sup>st</sup> line	III	30	17	2007	Ongoing
Myeloma	I	36	3		Ongoing
Myeloma	IV	550	82		Ongoing
Myeloma	IV	300	60	2001	2003
Breast, NSCLC, Colon--Supportive care Antiemetic	II	33/16	14	2006	2007
Breast--Supportive care Bone Mets	III	3	12	2006	2007
Bone Mets--Supportive care	III	23	8	2006	2008
NSCLC--Supportive care Cancer Cachexia	II	50	13	2008	Ongoing